HALIX

Operating from a 6,700 sq.m. new facility in the Netherlands, we are a global CDMO focused on mammalian expression systems for the production of immune stimulating viruses and antibodies. We use scalable SU, state-of-the-art bioprocessing technologies to provide services for the development and GMP manufacturing of DS as well as DP. We’ve entered into a number of contracts for the production of oncolytic immunotherapies and vaccines, most notably the large-scale commercial drug substance manufacture of AstraZeneca’s COVID-19 vaccine.